Investing.com - Financial Markets Worldwide

Iteos Therapeutics Inc (ITOS)

NASDAQ
Currency in USD
10.11
-0.02(-0.20%)
Closed·
After Hours
10.110.00(0.00%)
·
ITOS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ITOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
10.1010.15
52 wk Range
4.8018.13
Key Statistics
Edit
Prev. Close
10.13
Open
10.15
Day's Range
10.1-10.15
52 wk Range
4.8-18.13
Volume
1.02M
Average Volume (3m)
1.71M
1-Year Change
-31.27%
Book Value / Share
12.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ITOS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
10.30
Upside
+1.88%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 9
Quickly burning through cash
Unlock InvestingPro

Iteos Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Iteos Therapeutics Inc Company Profile

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company’s lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
173
Market
United States

Compare ITOS to Peers and Sector

Metrics to compare
ITOS
Peers
Sector
Relationship
P/E Ratio
−2.2x−1.1x−0.5x
PEG Ratio
0.04−0.040.00
Price/Book
0.9x2.2x2.6x
Price / LTM Sales
-8.9x3.3x
Upside (Analyst Target)
−0.1%318.8%43.4%
Fair Value Upside
Unlock18.2%7.1%Unlock

Analyst Ratings

0 Buy
5 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 10.30
(+1.88% Upside)

Earnings

Latest Release
Apr 28, 2025
EPS / Forecast
-0.80 / -0.93
Revenue / Forecast
-- / 2.25M
EPS Revisions
a
a
Unlock
Last 90 days

ITOS Income Statement

People Also Watch

AeroVironment
247.45
AVAV
-4.68%
Replimune
5.29
REPL
-3.47%
Sarepta
18.23
SRPT
+1.50%
Capricor Therapeutics
9.070
CAPR
+12.39%
CorMedix
10.330
CRMD
-4.44%

FAQ

What Stock Exchange Does Iteos Trade On?

Iteos is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Iteos?

The stock symbol for Iteos is "ITOS."

What Is the Iteos Market Cap?

As of today, Iteos market cap is 446.92M.

What Is Iteos's Earnings Per Share (TTM)?

The Iteos EPS (TTM) is -4.68.

When Is the Next Iteos Earnings Date?

Iteos will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is ITOS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Iteos Stock Split?

Iteos has split 0 times.

How Many Employees Does Iteos Have?

Iteos has 173 employees.

What is the current trading status of Iteos (ITOS)?

As of 10 Aug 2025, Iteos (ITOS) is trading at a price of 10.11, with a previous close of 10.13. The stock has fluctuated within a day range of 10.10 to 10.15, while its 52-week range spans from 4.80 to 18.13.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.